In the present study, LTB-RBD (a chimeric protein comprising a mucosal adjuvant carrier (LTB) and a segment from the RBD of SARS-CoV-2) was produced and purified as an antigen vaccine candidate for the formulation of mucosal vaccines against COVID-19. This evidence concerns the gene LTB and COVID-19.